Logan Capital Management Inc. decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% during the third quarter, Holdings Channel reports. The fund owned 52,423 shares of the biopharmaceutical company’s stock after selling 604 shares during the period. Logan Capital Management Inc.’s holdings in Gilead Sciences were worth $4,147,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Van Hulzen Asset Management LLC boosted its stake in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 100 shares in the last quarter. Penserra Capital Management LLC boosted its stake in shares of Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 774 shares in the last quarter. Gemmer Asset Management LLC boosted its stake in shares of Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 175 shares in the last quarter. Joel Isaacson & Co. LLC boosted its stake in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 226 shares in the last quarter. Finally, Roble Belko & Company Inc boosted its stake in shares of Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,035 shares in the last quarter. Hedge funds and other institutional investors own 73.43% of the company’s stock.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded up 0.03% during trading on Friday, reaching $73.38. 3,565,855 shares of the company’s stock traded hands. The company has a 50 day moving average of $73.96 and a 200-day moving average of $77.97. Gilead Sciences, Inc. has a 1-year low of $70.83 and a 1-year high of $103.10. The company has a market capitalization of $96.67 billion, a price-to-earnings ratio of 6.79 and a beta of 1.20.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $2.75 EPS for the quarter, missing the Zacks’ consensus estimate of $2.87 by $0.12. Gilead Sciences had a return on equity of 100.57% and a net margin of 47.74%. The business had revenue of $7.40 billion for the quarter, compared to analyst estimates of $7.47 billion. During the same quarter in the previous year, the business posted $3.22 earnings per share. The company’s revenue was down 9.6% compared to the same quarter last year. Equities analysts predict that Gilead Sciences, Inc. will post $11.47 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th were given a dividend of $0.47 per share. The ex-dividend date was Tuesday, December 13th. This represents a $1.88 dividend on an annualized basis and a yield of 2.56%. Gilead Sciences’s payout ratio is presently 17.44%.

TRADEMARK VIOLATION NOTICE: This piece of content was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international copyright and trademark laws. The legal version of this piece of content can be accessed at http://www.watchlistnews.com/gilead-sciences-inc-gild-stake-cut-by-logan-capital-management-inc/1060155.html.

GILD has been the subject of a number of recent analyst reports. RBC Capital Markets dropped their price target on shares of Gilead Sciences from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Wednesday, November 2nd. Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $84.73 price target for the company. in a research report on Wednesday, January 4th. Piper Jaffray Companies reiterated an “overweight” rating on shares of Gilead Sciences in a research report on Saturday, October 22nd. Jefferies Group reiterated a “buy” rating on shares of Gilead Sciences in a research report on Tuesday, November 8th. Finally, Credit Suisse Group set a $93.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, December 20th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $96.18.

In other Gilead Sciences news, insider John C. Martin sold 73,337 shares of the firm’s stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total transaction of $5,396,869.83. Following the completion of the sale, the insider now directly owns 3,204,433 shares in the company, valued at approximately $235,814,224.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $74.86, for a total value of $7,860,300.00. Following the sale, the director now owns 121,761 shares of the company’s stock, valued at $9,115,028.46. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.